Strong Memorial Hospital
- Type
- Teaching hospital
- Where
- ROCHESTER, NY
- Medicare CCN
- 330285
- Received
- $31,776,868 in 1,373 records, 2021 ($6,406,081 general, $25,370,787 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STRONG MEMORIAL HOSPITAL Fuzzy (name and state)
- Lobbying client: STRONG MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 189 | $6,406,081 |
| 2021 | Research payment | 1,184 | $25,370,787 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,184 | $25,370,787 |
| Royalty or License | 21 | $4,744,291 |
| Grant | 45 | $858,167 |
| Long term medical supply or device loan | 16 | $287,273 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 11 | $275,523 |
| Consulting Fee | 30 | $118,749 |
| Education | 9 | $59,666 |
| Space rental or facility fees (teaching hospital only) | 43 | $51,010 |
| Gift | 8 | $8,150 |
| Charitable Contribution | 6 | $3,250 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $700,891 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $338,759 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $231,007 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $175,746 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $63,440 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Microgenics Corporation | $49,755 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SM 25-HYDROXY VITAMIN D - ASSAY Device, TDM | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $39,083 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $28,651 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $26,107 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Pla | 2021 |
| 2021-12-31 | bioMerieux Inc | $20,000 | Research payment | Cash or cash equivalent | VITEK 2 Device, Diagnostics | MICRO - VITEK 2_USA_ROCHESTER_HARDY_2020_BIR_GP21 | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $13,750 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in comb | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,622 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in comb | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $12,398 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,705 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,113 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously S | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,032 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $8,288 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $7,571 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,977 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,228 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-31 | AstraZeneca UK Limited | $4,166 | Research payment | In-kind items and services | FASENRA Biological, Respiratory | A Phase 2 Multinational Randomized Double blind Parallel group 16 week Placebo controlled Study with a 36 week Extension | 2021 |
| 2021-12-31 | ABBVIE INC. | $3,796 | Research payment | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | A Multicenter, Non-Drug Interventional Study for the Technical Development and Validation of the Nocturnal Scratch Algor | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $3,423 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $3,400 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,779 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $2,739 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | ROCHE MOLECULAR SYSTEMS, INC. | $2,043 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD006042 | 2021 |
| 2021-12-31 | ABBVIE INC. | $1,802 | Research payment | In-kind items and services | An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $1,541 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Proof of Concept Study of the Combination of ACP196 and ACP319 in Subjects with Bcell Malignancies | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,365 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,314 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous | 2021 |
| 2021-12-31 | Takeda Pharmaceuticals U.S.A., Inc. | $1,211 | Research payment | Cash or cash equivalent | FIRAZYR Drug, IMMUNOLOGY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,115 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pem | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $938 | Research payment | Cash or cash equivalent | UR2020MRIPR990Weinberg | 2021 | |
| 2021-12-31 | ABBVIE INC. | $903 | Research payment | In-kind items and services | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABB | 2021 | |
| 2021-12-31 | Omeros Corporation | $858 | Research payment | Cash or cash equivalent | An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $840 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with | 2021 |
| 2021-12-31 | Abbott Laboratories | $622 | Research payment | In-kind items and services | HeartMate 3 Left Ventricular Assist Device Device, Heart Failure | PHP SHIELD II | 2021 |
| 2021-12-31 | Abbott Laboratories | $622 | Research payment | In-kind items and services | HeartMate 3 Left Ventricular Assist Device Device, Heart Failure | PHP SHIELD II | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $448 | Research payment | In-kind items and services | Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with R | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $393 | Research payment | Cash or cash equivalent | UR2021MRIPR794Tawil | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $387 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $180 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | AstraZeneca UK Limited | $63 | Research payment | In-kind items and services | A Platform Protocol for the Treatment of Relapsed /Refractory Aggressive Non-Hodgkin's Lymphoma | 2021 | |
| 2021-12-31 | Aimmune Therapeutics, Inc. | $21 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-12-31 | AstraZeneca UK Limited | $20 | Research payment | In-kind items and services | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo | 2021 | |
| 2021-12-31 | AngioDynamics, Inc. | $9 | Education | In-kind items and services | C3 WAVE SYSTEM Device, Vascular Access | 2021 | |
| 2021-12-30 | AERIN MEDICAL INC. | $13,184 | Research payment | Cash or cash equivalent | VIVAER STYLUS Device, EAR NOSE & THROAT | CTP 1125 - SWELL | 2021 |
| 2021-12-29 | United Therapeutics Corporation | $100,000 | Research payment | Cash or cash equivalent | 2021 | ||
| 2021-12-28 | PFIZER INC. | $2,020 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-28 | PFIZER INC. | $414 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-27 | UCB SA | $12,335 | Research payment | Cash or cash equivalent | A Multicenter, open-label study to evaluate the pharmacokinetics, Tolerability, and Safety of a Single dose of staccato | 2021 | |
| 2021-12-25 | PFIZER INC. | $828 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-23 | ROCHE MOLECULAR SYSTEMS, INC. | $34,822 | Research payment | Cash or cash equivalent | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD006041 | 2021 |
| 2021-12-23 | PFIZER INC. | $7,722 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INF | 2021 | |
| 2021-12-23 | PFIZER INC. | $3,312 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-23 | PFIZER INC. | $891 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INF | 2021 | |
| 2021-12-22 | Alexion Pharmaceuticals, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-12-22 | GE HEALTHCARE | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DATSCAN Drug, CORE IMAGING | 2021 | |
| 2021-12-21 | PFIZER INC. | $50,734 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2021 | |
| 2021-12-21 | Janssen Research & Development, LLC | $27,270 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-21 | PFIZER INC. | $22,833 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-21 | Janssen Research & Development, LLC | $6,982 | Research payment | Cash or cash equivalent | An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B | 2021 | |
| 2021-12-21 | SANOFI PASTEUR INC. | $5,292 | Research payment | Cash or cash equivalent | Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy A | 2021 | |
| 2021-12-21 | PFIZER INC. | $3,211 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-12-21 | Genentech, Inc. | $2,340 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY FOR MODERATE AD | 2021 |
| 2021-12-20 | Eisai Inc. | $46,548 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 | |
| 2021-12-20 | Gilead Sciences, Inc. | $7,387 | Research payment | Cash or cash equivalent | A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects with Primary Sclero | 2021 | |
| 2021-12-20 | Eisai Inc. | $5,463 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 | |
| 2021-12-20 | Genentech, Inc. | $5,070 | Research payment | Cash or cash equivalent | Drug | HCRU AMONG MEDICARE ENROLLED PTS PARTICIPATING IN SPONSOR CONDUCTED PHASE III CLINICAL TRIALS IN AD | 2021 |
| 2021-12-20 | Genentech, Inc. | $2,579 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2021 |
| 2021-12-20 | Genentech, Inc. | $2,210 | Research payment | Cash or cash equivalent | Drug | GANTENERUMAB IN EARLY AD | 2021 |
| 2021-12-17 | Janssen Research & Development, LLC | $20,036 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-16 | GRT US Holding, Inc. | $281,596 | Research payment | Cash or cash equivalent | Qutenza Drug, Pain Management | PSMP | 2021 |
| 2021-12-16 | NeuroMetrix Inc | $6,419 | Research payment | Cash or cash equivalent | Quell Device, Pain Management | Quell Pain Management System for Reducing Chronic Chemotherapy-induced Peripheral Neuropathic Pain | 2021 |
| 2021-12-16 | SEAGEN INC. | $2,275 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $2,193 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-12-16 | Genentech, Inc. | $1,761 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY FOR MODERATE AD | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $534 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2021 |
| 2021-12-16 | Travere Therapeutics, Inc. | $487 | Research payment | Cash or cash equivalent | Cholbam Drug, Hepatology | The Replace Registry | 2021 |
| 2021-12-16 | Neurocrine BioSciences, Inc. | $58 | Research payment | In-kind items and services | INGREZZA Drug, NEUROLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VALBEN | 2021 |
| 2021-12-15 | Kaneka Medical America LLC | $4,410 | Consulting Fee (12 payments) | Cash or cash equivalent | LIPOSORBER Device, Lipid Apheresis | 2021 | |
| 2021-12-15 | Biohaven Pharmaceuticals, Inc. | $2,305 | Research payment | Cash or cash equivalent | A Phase IIb/III Randomized Double-blind Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar A | 2021 | |
| 2021-12-15 | Intercept Pharmaceuticals, Inc. | $1,240 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-12-14 | PFIZER INC. | $17,248 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-14 | SEAGEN INC. | $16,550 | Research payment | Cash or cash equivalent | A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma | 2021 | |
| 2021-12-14 | SEAGEN INC. | $14,500 | Research payment | Cash or cash equivalent | A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma | 2021 | |
| 2021-12-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | Plexa Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-13 | Genentech, Inc. | $6,727 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | POLARIX | 2021 |
| 2021-12-12 | SANOFI PASTEUR INC. | $200 | Space rental or facility fees (teaching hospital only) | In-kind items and services | VAXELIS Biological, Vaccines | 2021 | |
| 2021-12-09 | Janssen Research & Development, LLC | $9,214 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | Pilot trial of Ustekinumab for Primary Sjogren's Syndrome | 2021 |
| 2021-12-09 | Bayer Healthcare Pharmaceuticals Inc. | $7,893 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2021 |
| 2021-12-09 | Novartis Pharmaceuticals Corporation | $7,332 | Research payment | Cash or cash equivalent | Drug | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2021 |
| 2021-12-09 | Janssen Research & Development, LLC | $3,246 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Su | 2021 | |
| 2021-12-09 | Intercept Pharmaceuticals, Inc. | $2,205 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-12-09 | Pharmacyclics LLC, an AbbVie Company | $892 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | 2021 |
| 2021-12-08 | Merck Sharp & Dohme LLC | $92,967 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2021 |
| 2021-12-08 | Genentech, Inc. | $28,857 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY FOR MODERATE AD | 2021 |
| 2021-12-08 | AstraZeneca Pharmaceuticals LP | $15,983 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Randomized Double-blind Placebo-controlled Phase III Study of Neoadjuvant Adjuvant Durvalumab and FLOT Chemotherapy Fo | 2021 |
| 2021-12-08 | Incyte Corporation | $10,950 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2021 | |
| 2021-12-08 | Incyte Corporation | $4,350 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2021 | |
| 2021-12-08 | Incyte Corporation | $1,950 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2021 | |
| 2021-12-08 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2021 | |
| 2021-12-08 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2021 | |
| 2021-12-08 | Edwards Lifesciences Corporation | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | 2021 | |
| 2021-12-08 | Incyte Corporation | $910 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2021 | |
| 2021-12-08 | Roche TCRC, Inc. | $635 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2021 |
| 2021-12-07 | Eisai Inc. | $71,200 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 | |
| 2021-12-07 | Eisai Inc. | $26,520 | Research payment | Cash or cash equivalent | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lor | 2021 | |
| 2021-12-07 | PFIZER INC. | $24,661 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-07 | Janssen Research & Development, LLC | $15,945 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-07 | Janssen Research & Development, LLC | $357 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-12-06 | SANOFI PASTEUR INC. | $16,969 | Research payment | Cash or cash equivalent | Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy A | 2021 | |
| 2021-12-06 | Bayer Healthcare Pharmaceuticals Inc. | $3,680 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2021 |
| 2021-12-06 | Gilead Sciences, Inc. | $2,443 | Research payment | Cash or cash equivalent | A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects with Primary Sclero | 2021 | |
| 2021-12-06 | Pharmacyclics LLC, an AbbVie Company | $583 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2021 |
| 2021-12-04 | PFIZER INC. | $26,027 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2021 | |
| 2021-12-04 | PFIZER INC. | $24,055 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INF | 2021 | |
| 2021-12-04 | PFIZER INC. | $2,090 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INF | 2021 | |
| 2021-12-04 | PFIZER INC. | $741 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-12-04 | PFIZER INC. | $414 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-03 | Karyopharm Therapeutics Inc. | $167,359 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | Evaluating the impact of novel inhibitors of nuclear pore export in SLE | 2021 |
| 2021-12-03 | Karyopharm Therapeutics Inc. | $61,779 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | Evaluating the impact of novel inhibitors of nuclear pore export in SLE | 2021 |
| 2021-12-03 | Karyopharm Therapeutics Inc. | $37,688 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | Evaluating the impact of novel inhibitors of nuclear pore export in SLE | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $27,167 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-03 | Karyopharm Therapeutics Inc. | $22,225 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | Evaluating the impact of novel inhibitors of nuclear pore export in SLE | 2021 |
| 2021-12-03 | Janssen Research & Development, LLC | $3,652 | Research payment | Cash or cash equivalent | An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B | 2021 | |
| 2021-12-03 | Takeda Pharmaceuticals U.S.A., Inc. | $1,068 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2021 | |
| 2021-12-03 | Ipsen Bioscience Inc. | $903 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $903 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $818 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $818 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $688 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $668 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-02 | Travere Therapeutics, Inc. | $2,925 | Research payment | Cash or cash equivalent | Cholbam Drug, Hepatology | The Replace Registry | 2021 |
| 2021-12-02 | ABBVIE INC. | $2,815 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Multicenter, Non-Drug Interventional Study for the Technical Development and Validation of the Nocturnal Scratch Algor | 2021 |
| 2021-12-02 | Amryt Pharma Holdings Ltd | $1,040 | Research payment | Cash or cash equivalent | MYCAPSSA Drug, Endocrinology | MACRO Registry | 2021 |
| 2021-12-02 | Allergan, Inc. | $995 | Grant | Cash or cash equivalent | BOTOX Biological, HYPERHYDROSIS | 2021 | |
| 2021-12-02 | Abbott Laboratories | $755 | Research payment | Cash or cash equivalent | Absorb GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2021 |
| 2021-12-02 | ABBVIE INC. | $730 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Multicenter, Non-Drug Interventional Study for the Technical Development and Validation of the Nocturnal Scratch Algor | 2021 |
| 2021-12-01 | Ortho-Clinical Diagnostics, Inc. | $35,866 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-12-01 | Ortho-Clinical Diagnostics, Inc. | $35,866 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-12-01 | Genentech, Inc. | $27,541 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2021 |
| 2021-12-01 | PFIZER INC. | $17,557 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-01 | Eisai Inc. | $5,440 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease | 2021 | |
| 2021-12-01 | Eisai Inc. | $2,580 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease | 2021 | |
| 2021-11-30 | ROCHE MOLECULAR SYSTEMS, INC. | $2,043 | Research payment | In-kind items and services | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System Device, Molecular Diagnostics | RD006042 | 2021 |
| 2021-11-30 | PFIZER INC. | $828 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-11-30 | Leadiant Biosciences, Inc. | $169 | Research payment | Cash or cash equivalent | Drug, Neuromuscular Disease | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with G | 2021 |
| 2021-11-30 | Abbott Laboratories | $140 | Research payment | In-kind items and services | HeartMate 3 Left Ventricular Assist Device Device, Heart Failure | HM3 SWIFT PMS | 2021 |
| 2021-11-30 | Boston Scientific Corporation | $100 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-11-29 | SANOFI US SERVICES INC. | $1,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab i | 2021 |
| 2021-11-26 | Genentech, Inc. | $950 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2021 |
| 2021-11-25 | Abbott Laboratories | $2,000 | Education | Cash or cash equivalent | 2021 | ||
| 2021-11-24 | PFIZER INC. | $18,891 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-11-24 | United Therapeutics Corporation | $4,747 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2021 |
| 2021-11-23 | United Therapeutics Corporation | $6,671 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-11-23 | PFIZER INC. | $1,732 | Research payment | Cash or cash equivalent | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY | 2021 | |
| 2021-11-23 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $1,638 | Research payment | Cash or cash equivalent | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2021 | |
| 2021-11-23 | United Therapeutics Corporation | $1,476 | Research payment | Cash or cash equivalent | A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION | 2021 | |
| 2021-11-23 | Relievant Medsystems, Inc. | $845 | Research payment | Cash or cash equivalent | Intracept Device, Pain | Intracept | 2021 |
| 2021-11-23 | PFIZER INC. | $828 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-11-23 | SEAGEN INC. | $208 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-11-23 | SEAGEN INC. | $208 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-11-22 | Genentech, Inc. | $125,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-22 | Kite Pharma, Inc. | $75,595 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphom | 2021 |
| 2021-11-22 | SANOFI PASTEUR INC. | $17,980 | Research payment | Cash or cash equivalent | Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy A | 2021 | |
| 2021-11-22 | GENZYME CORPORATION | $1,125 | Research payment | Cash or cash equivalent | LEMTRADA Biological, Neurology | A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profi | 2021 |
| 2021-11-22 | SK Life Science, Inc. | $995 | Education | Cash or cash equivalent | XCOPRI Drug, Neurology | 2021 | |
| 2021-11-22 | Paratek Pharmaceuticals, Inc. | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | 2021 | |
| 2021-11-22 | GENZYME CORPORATION | $900 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2021 | |
| 2021-11-22 | GENZYME CORPORATION | $225 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-11-20 | PFIZER INC. | $59,615 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INF | 2021 | |
| 2021-11-20 | PFIZER INC. | $49,435 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2021 | |
| 2021-11-20 | PFIZER INC. | $23,244 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INF | 2021 | |
| 2021-11-20 | PFIZER INC. | $14,172 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-11-19 | Eisai Inc. | $20,649 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 | |
| 2021-11-19 | Eisai Inc. | $4,121 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Stud | 2021 | |
| 2021-11-19 | Eisai Inc. | $2,904 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Stud | 2021 | |
| 2021-11-19 | Eisai Inc. | $2,531 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Stud | 2021 | |
| 2021-11-18 | ABBVIE INC. | $3,469 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Multicenter, Non-Drug Interventional Study for the Technical Development and Validation of the Nocturnal Scratch Algor | 2021 |
| 2021-11-18 | Medtronic, Inc. | $2,493 | Research payment | Cash or cash equivalent | Investigator Sponsored Research | 2021 | |
| 2021-11-18 | BIOTRONIK INC. | $1,700 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2021 | |
| 2021-11-18 | GENZYME CORPORATION | $995 | Space rental or facility fees (teaching hospital only) | In-kind items and services | DUPIXENT Biological, Immunology | 2021 | |
| 2021-11-18 | Regeneron Healthcare Solutions, Inc. | $995 | Grant | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2021 | |
| 2021-11-17 | Gilead Sciences, Inc. | $7,056 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-11-17 | PFIZER INC. | $6,950 | Research payment | Cash or cash equivalent | DAURISMO Drug, ONCOLOGY | A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASD | 2021 |
| 2021-11-17 | Ortho-Clinical Diagnostics, Inc. | $5,926 | Research payment | Cash or cash equivalent | VITROS 4600 Chemistry System Device, Diagnostics | wrCRP MicroTip | 2021 |
| 2021-11-17 | PFIZER INC. | $4,160 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-11-17 | Karyopharm Therapeutics Inc. | $3,046 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myel | 2021 |
| 2021-11-17 | Karyopharm Therapeutics Inc. | $2,902 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myel | 2021 |
| 2021-11-17 | Abbott Laboratories | $2,586 | Research payment | Cash or cash equivalent | HeartMate 3 Left Ventricular Assist Device Device, Heart Failure | Antiplatelet Removal and HemocompatIbility EventS in the HeartMate 3 Pump | 2021 |
| 2021-11-17 | Abbott Laboratories | $2,586 | Research payment | Cash or cash equivalent | HeartMate 3 Left Ventricular Assist Device Device, Heart Failure | Antiplatelet Removal and HemocompatIbility EventS in the HeartMate 3 Pump | 2021 |
| 2021-11-17 | Karyopharm Therapeutics Inc. | $2,559 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myel | 2021 |
| 2021-11-17 | PFIZER INC. | $2,419 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-11-17 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,950 | Research payment | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | BMAD | 2021 |
| 2021-11-17 | Karyopharm Therapeutics Inc. | $1,279 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myel | 2021 |
The latest 200 records of 1,373.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rochester, NY, county Monroe County, NY, state New York; placed by its city name.
| Measure | Place (city or town) Rochester, NY | County Monroe County, NY | State New York |
|---|---|---|---|
| Population B01003 | 208,772 | 753,753 | 19,852,366 |
| Population, 2020 census P1 | 211,328 | 759,443 | 20,201,249 |
| Median age B01002 | 33.7 | 39.6 | 39.8 |
| Under 18 B01001 | 20.9% | 20.3% | 20.5% |
| 65 and over B01001 | 13.1% | 18.8% | 17.9% |
| Households B11001 | 93,261 | 318,428 | 7,722,646 |
| Foreign born B05002 | 8.2% | 7.9% | 22.8% |
| Median household income B19013 | $47,213 | $76,382 | $85,974 |
| Median family income B19113 | $57,673 | $102,166 | $106,873 |
| Per capita income B19301 | $31,314 | $44,107 | $50,712 |
| Poverty rate B17001 | 27.8% | 13.6% | 14.0% |
| Unemployment rate B23025 | 7.9% | 4.9% | 6.4% |
| Civilian labor force B23025 | 105,136 | 391,197 | 10,171,766 |
| Mean commute (minutes) B08013 | 19.3 | 19.9 | 32.6 |
| Bachelor's degree or higher B15003 | 30.0% | 41.5% | 40.2% |
| Housing units B25001 | 104,479 | 339,430 | 8,585,241 |
| Owner-occupied B25003 | 38.1% | 63.7% | 54.3% |
| Renters B25003 | 61.9% | 36.3% | 45.7% |
| Median home value B25077 | $139,600 | $213,700 | $423,800 |
| Median gross rent B25064 | $1,081 | $1,173 | $1,621 |
| White, not Hispanic B03002 | 36.4% | 67.7% | 52.8% |
| Black B03002 | 34.7% | 13.5% | 13.4% |
| Hispanic or Latino B03002 | 19.6% | 9.9% | 19.8% |
| Asian B03002 | 3.2% | 3.8% | 9.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rochester, NY.
Comments